15 September 2022  
EMA/759875/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Evusheld 
tixagevimab / cilgavimab 
On 15 September 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Evusheld. The marketing authorisation holder for this medicinal product is AstraZeneca AB. 
The CHMP adopted an extension to the existing indication for Evusheld to include the treatment of 
COVID-19 in adults and adolescents. 
For information, the full indication for Evusheld will be as follows:2 
Pre-exposure prophylaxis 
Evusheld is indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents 
aged 12 years and older weighing at least 40 kg (see sections 4.2, 5.1 and 5.2). 
Treatment 
Evusheld is indicated for the treatment of adults and adolescents (aged 12 years and 
older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen 
and who are at increased risk of progressing to severe COVID-19 (see sections 4.2, 5.1 
and 5.2). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union  
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
